院前氨甲环酸对创伤性颅内出血患者死亡率和神经功能结局的影响:一项来自院前氨甲环酸治疗创伤性脑损伤试验的亚组分析
该研究为院前氨甲环酸治疗创伤性脑损伤试验的二次分析,纳入初始CT显示颅内出血的541例患者。患者被随机分为院前2克氨甲环酸推注+院内生理盐水输注组、院前1克氨甲环酸推注+院内1克氨甲环酸输注组或安慰剂组。结果发现,2克推注组28天死亡率为17%,低于1克推注/1克输注组的26%和安慰剂组的27%,调整后差异分别为-10.2和-8.5个百分点;6个月残疾评定量表评分也低于其他两组,但6个月扩展格拉斯哥结局量表评分无组间差异。
要点
- 在541例中重度创伤性脑损伤合并颅内出血患者中,院前2克氨甲环酸推注组28天死亡率为17%,1克推注/1克输注组为26%,安慰剂组为27%。
- 2克推注组与安慰剂组28天死亡率调整后差异为-8.5个百分点(95%CI -15.9至-1.0),与1克推注/1克输注组差异为-10.2个百分点(95%CI -17.6至-2.9)。
- 6个月残疾评定量表评分:2克推注组较1克推注/1克输注组低2.1分(95%CI -4.2至-0.02),较安慰剂组低2.2分(95%CI -4.3至-0.2)。
- 6个月扩展格拉斯哥结局量表(GOSE)评分在各组间无差异。
适用人群与场景
- 中重度创伤性脑损伤(格拉斯哥昏迷评分<13)且收缩压≥90毫米汞柱的成人患者,在受伤后2小时内纳入。
- 本分析仅纳入初始CT显示颅内出血的亚组患者。
诊断标准与关键阈值
- 中重度创伤性脑损伤定义为格拉斯哥昏迷评分<13。
- 颅内出血通过初始CT诊断。
处置流程与药物剂量
- 院前2克氨甲环酸推注,随后院内生理盐水输注。
- 院前1克氨甲环酸推注,随后院内1克氨甲环酸输注。
- 院前生理盐水推注,随后院内生理盐水输注(安慰剂)。
研究设计与关键结果
- 研究类型:院前氨甲环酸治疗创伤性脑损伤试验(NCT01990768)的二次分析,该试验随机对照了966例患者。
- 本分析纳入541例初始CT显示颅内出血的患者。
- 28天死亡率:2克推注组17%,1克推注/1克输注组26%,安慰剂组27%。
- 2克推注组与安慰剂组28天死亡率调整后差异为-8.5个百分点(95%CI -15.9至-1.0)。
- 2克推注组与1克推注/1克输注组28天死亡率调整后差异为-10.2个百分点(95%CI -17.6至-2.9)。
- 6个月残疾评定量表评分:2克推注组较1克推注/1克输注组低2.1分(95%CI -4.2至-0.02),较安慰剂组低2.2分(95%CI -4.3至-0.2)。
- 6个月扩展格拉斯哥结局量表评分在各组间无差异。
证据类型、等级与局限
- 证据类型:随机对照试验的亚组分析。
- 证据等级:治疗/护理管理;Level II。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于中重度创伤性脑损伤合并颅内出血的患者,院前2克氨甲环酸单次推注可能降低28天死亡率和6个月残疾评定量表评分,作者认为该结果优于安慰剂和标准氨甲环酸给药方案。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In the prehospital tranexamic acid (TXA) for traumatic brain injury (TBI) trial, TXA administered within 2 hours of injury in the out-of-hospital setting did not reduce mortality in all patients with moderate/severe traumatic brain injury (TBI). We examined the association between TXA dosing arms, neurologic outcome, and mortality in patients with intracranial hemorrhage (ICH) on computed tomography (CT).
METHODS: This was a secondary analysis of the Prehospital Tranexamic Acid for TBI Trial ( ClinicalTrials.gov [NCT01990768]) that randomized adults with moderate/severe TBI (Glasgow Coma Scale score < 13) and systolic blood pressure ≥ 90 mm Hg within 2 hours of injury to a 2-g out-of-hospital TXA bolus followed by an in-hospital saline infusion, a 1-g out-of-hospital TXA bolus/1-g in-hospital TXA infusion, or an out-of-hospital saline bolus/in-hospital saline infusion (placebo). This analysis included the subgroup with ICH on initial CT. Primary outcomes included 28-day mortality, 6-month Glasgow Outcome Scale-Extended (GOSE) ≤ 4, and 6-month Disability Rating Scale (DRS). Outcomes were modeled using linear regression with robust standard errors.
RESULTS: The primary trial included 966 patients. Among 541 participants with ICH, 28-day mortality was lower in the 2-g TXA bolus group (17%) compared with the other two groups (1-g bolus/1-g infusion 26%, placebo 27%). The estimated adjusted difference between the 2-g bolus and placebo groups was -8·5 percentage points (95% confidence interval [CI], -15.9 to -1.0) and between the 2-g bolus and 1-g bolus/1-g infusion groups was -10.2 percentage points (95% CI, -17.6 to -2.9). Disability Rating Scale at 6 months was lower in the 2-g TXA bolus group than the 1-g bolus/1-g infusion (estimated difference - 2.1 [95% CI, -4.2 to -0.02]) and placebo groups (-2.2 [95% CI, -4.3, -0.2]). Six-month GOSE did not differ among groups.
CONCLUSION: A 2-g out-of-hospital TXA bolus in patients with moderate/severe TBI and ICH resulted in lower 28-day mortality and lower 6-month DRS than placebo and standard TXA dosing.
LEVEL OF EVIDENCE: Therapeutic/Care Management; Level II.
参考来源
- Rowell S, Meier EN, Hoyos Gomez T, et al. The effects of prehospital TXA on mortality and neurologic outcomes in patients with traumatic intracranial hemorrhage: A subgroup analysis from the prehospital TXA for TBI trial. J Trauma Acute Care Surg. 2024. PMID: 38685481. doi:10.1097/TA.0000000000004354
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。